Why the study?
Diabetic cardiomyopathy pathophysiology remains multifactorial and poorly understood, with no specific established therapeutic guidelines.
This review summarizes the pathophysiology, diagnostic challenges, and potential therapeutic interventions for diabetic cardiomyopathy.
Alerts clinicians to diagnostic challenges in diabetic cardiomyopathy; leaves open validation of potential interventions in prospective trials.
Diabetic patients are predisposed to diabetic cardiomyopathy, a specific form of cardiomyopathy which is characterized by the development of myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis that develops independently of concomitant macrovascular and microvascular diabetic complications. Its pathophysiology is multifactorial and poorly understood and no specific therapeutic guideline has yet been established. Diabetic cardiomyopathy is a challenging diagnosis, made after excluding other potential entities, treated with different pharmacotherapeutic agents targeting various pathophysiological pathways that need yet to be unraveled. It has great clinical importance as diabetes is a disease with pandemic proportions. This review focuses on the potential mechanisms contributing to this entity, diagnostic options, as well as on potential therapeutic interventions taking in consideration their clinical feasibility and limitations in everyday practice. Besides conventional therapies, we discuss novel therapeutic possibilities that have not yet been translated into clinical practice.
No takes yet. Share an insight, caveat, or question.
Rotkvić et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: